Oncolix, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-07-03: Form 8-K; Period of report 2019-07-02; Description 8.01 Other Events; Details 8.01.
- 2019-03-11: Form 8-K; Period of report 2019-03-06; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2019-02-21: Form 8-K; Period of report 2019-02-18; Description 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.01.
- 2019-01-28: Form 8-K; Period of report 2019-01-23; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-07-03 | 8-K | 2019-07-02 | 8.01 Other Events | 8.01 On July 2, 2019, the Company received a final notice of default under its license agreement for CycloSam, its product candidate. | oncx_8k.htm |
| 2019-03-11 | 8-K | 2019-03-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Between March 6, 2019 and March 11, 2019, Oncolix, Inc. (the “Company”) received the resignations of Dale Zajicek, Jerry Youkey, Sherry Grisewood and John Holaday as members of the Board of Directors. 8.01 On March 7, 2019, the Company received a notice of default under its license agreement for CycloSam, its product candidate. | oncx_8k.htm |
| 2019-02-21 | 8-K | 2019-02-18 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 3.03 The Company created a designation of Series B Preferred Stock (as specified in the Certificate of Designation). 5.03 On February 18, 2019, the Company filed the Certificate of Designation. | oncx_8k.htm |
| 2019-01-28 | 8-K | 2019-01-23 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 3.01 On January 23, 2019, Oncolix, Inc. (the Company) was notified by the OTCMarkets that its shares of common stock had a closing bid on OTCQB for 30 consecutive calendar days of less than $0.01, which violate the listing requirements for OTCMarkets. 3.02 The disclosure set forth in Item 8.01 is incorporated herein by reference. 5.02 On January 11, 2019, Donald Payne resigned his position as Secretary of the Company and provided written notice of his intention to terminate his part-time employment in 35 days. 8.01 In December 2018, the Company engaged a consultant to assist it in analyzing financing alternatives for the Company. | oncx_8k.htm |
| 2019-01-02 | 8-K | 2018-11-29 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 8.01 Other Events | 1.01 The disclosure set forth in Item 2.04 is incorporated herein by reference. 2.03 The disclosure set forth in Item 2.04 is incorporated herein by reference. 2.04 Oncolix, Inc., a Florida corporation (“Company”), has outstanding convertible notes in the principal amount of $5,407,757. 8.01 The Company is halting enrollment in its Phase I clinical trial of Prolanta for the treatment of ovarian cancer as a result of injection site reactions at the current dose level. | oncx_8k.htm |
| 2018-10-11 | 8-K | 2018-10-11 | 7.01 Regulation FD Disclosure | 7.01 Oncolix, Inc. (“Oncolix” or the “Company”) is furnishing this information pursuant to Item 7.01 of this Current Report, which information shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. | oncx_8k.htm |
| 2018-06-29 | 8-K | 2018-06-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 26, 2018, the Board of Directors of Oncolix, Inc. (the “Company”) voted to increase the number of Directors to five from the current four, and elected Sherry Grisewood to serve as a Director until her resignation or replacement by action of the stockholders of the Company. | oncx_8k.htm |
| 2018-06-27 | 8-K | 2018-06-25 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On June 25, 2018, Oncolix, Inc. (the “Company”) filed an amendment to its article of incorporation (the “Amendment”) with the Florida Secretary of State to increase the number of authorized shares of common stock, $0.0001 par value, to 8,000,000,000. 5.07 The description in Item 5.03 herein is incorporated by reference. | oncx_8k.htm |
| 2018-06-06 | 8-K | 2018-06-01 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders | 1.01 Entry into a Material Definitive Agreement. 2.03 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.02 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.03 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. | oncx_8k.htm |
| 2018-05-01 | 8-K | 2018-04-27 | 8.01 Other Events | 8.01 In August 2017, the Company issued convertible notes to the investors in an aggregate principal amount of $4,190,463 for a purchase price of $3,561,894 (“Convertible Notes”). | oncx_8k.htm |
| 2017-12-06 | 8-K | 2017-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 1, 2017, the Board of Directors of Oncolix, Inc. (the “Company”) voted to increase the number of Directors to four from the current three, and elected John Holaday PhD to serve as a Director until his resignation or replacement by action of the stockholders of the Company. | aepp_8k.htm |
| 2017-11-24 | 8-K/A | 2017-08-03 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 4.01 Changes in Registrant's Certifying Accountant; 5.01 Changes in Control of Registrant; 5.06 Change in Shell Company Status | 1.01 Entry into a Material Definitive Agreement. 2.01 For purposes of this Form 8-K, the Company is providing certain information that it would be required to disclose if it were a registrant filing a general form for registration of securities on Form 10 under the Exchange Act. 2.03 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.02 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.03 The disclosure set forth under Item 5.03 of this Form 8-K is incorporated by reference into this item. 4.01 On August 4, 2017, in connection with the Merger, the Board of Directors of the Company approved engagement of Pannell Kerr Forster of Texas, P.C. (“PKF”) as the independent registered public accounting firm for the Company. 5.01 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference to this item. 5.06 In connection with the transactions described in Item 1.01, the Company has ceased being a shell corporation as defined in Rule 12b-2 under the Exchange Act. | aepp_8ka.htm |
| 2017-11-14 | 8-K/A | 2017-08-03 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 4.01 Changes in Registrant's Certifying Accountant; 5.01 Changes in Control of Registrant; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.06 Change in Shell Company Status | 1.01 Entry into a Material Definitive Agreement. 2.01 For purposes of this Form 8-K, the Company is providing certain information that it would be required to disclose if it were a registrant filing a general form for registration of securities on Form 10 under the Exchange Act. 2.03 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.02 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.03 The disclosure set forth under Item 5.03 of this Form 8-K is incorporated by reference into this item. 4.01 On August 4, 2017, in connection with the Merger, the Board of Directors of the Company approved engagement of Pannell Kerr Forster of Texas, P.C. (“PKF”) as the independent registered public accounting firm for the Company. 5.01 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference to this item. 5.06 In connection with the transactions described in Item 1.01, the Company has ceased being a shell corporation as defined in Rule 12b-2 under the Exchange Act. | aepp_8ka.htm |
| 2017-10-26 | 8-K/A | 2017-08-03 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 4.01 Changes in Registrant's Certifying Accountant; 5.01 Changes in Control of Registrant; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.06 Change in Shell Company Status | 1.01 Entry into a Material Definitive Agreement. 2.01 For purposes of this Form 8-K, the Company is providing certain information that it would be required to disclose if it were a registrant filing a general form for registration of securities on Form 10 under the Exchange Act. 2.03 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.02 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.03 The disclosure set forth under Item 5.03 of this Form 8-K is incorporated by reference into this item. 4.01 On August 4, 2017, in connection with the Merger, the Board of Directors of the Company approved engagement of Pannell Kerr Forster of Texas, P.C. (“PKF”) as the independent registered public accounting firm for the Company. 5.01 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference to this item. 5.06 In connection with the transactions described in Item 1.01, the Company has ceased being a shell corporation as defined in Rule 12b-2 under the Exchange Act. | aepp_8ka.htm |
| 2017-10-11 | 8-K | 2017-10-11 | 7.01 Regulation FD Disclosure | 7.01 Oncolix, Inc. (the “Company”) has prepared a PowerPoint presentation attached hereto as Exhibit 99.1 which is incorporated herein by reference. | aepp_8k.htm |
| 2017-10-04 | 8-K | 2017-10-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 3, 2017, the Board of Directors of Oncolix, Inc. (the “Company”) voted to increase the number of Directors to three from the current two, and elected Jerry R Youkey MD and Dale Zajieck to serve as Directors until their resignation or replacement by action of the stockholders of the Company. | aepp_8k.htm |
| 2017-10-02 | 8-K | 2017-09-28 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On September 28, 2017, Advanced Environmental Petroleum Producers Inc. (the “Company”) filed an amendment to its article of incorporation (the “Amendment”) with the Florida Secretary of State to change its name to Oncolix, Inc. In addition, pursuant to the terms of its Agreement and Plan of Merger with Oncolix, Inc. as disclosed in August 2017, the Amendment (i) increased the number of authorized shares of common stock, $0.0001 par value, to 950,000,000, (ii) increased the number of authorized shares of preferred stock, $0.0001 par value, to 250,000,000, and (iii) increased the number of shares of preferred stock designated as Series A preferred stock to 150,000,000. 5.07 The description in Item 5.03 herein is incorporated by reference. | aepp_8k.htm |
| 2017-08-09 | 8-K | 2017-08-03 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 4.01 Changes in Registrant's Certifying Accountant; 5.01 Changes in Control of Registrant; 5.06 Change in Shell Company Status | 1.01 Entry into a Material Definitive Agreement. 2.01 For purposes of this Form 8-K, the Company is providing certain information that it would be required to disclose if it were a registrant filing a general form for registration of securities on Form 10 under the Exchange Act. 2.03 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.02 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference into this item. 3.03 The disclosure set forth under Item 5.03 of this Form 8-K is incorporated by reference into this item. 4.01 On August 4, 2017, in connection with the Merger, the Board of Directors of the Company approved engagement of Pannell Kerr Forster of Texas, P.C. (“PKF”) as the independent registered public accounting firm for the Company. 5.01 The disclosure set forth under Item 1.01 of this Form 8-K is incorporated by reference to this item. 5.06 In connection with the transactions described in Item 1.01, the Company has ceased being a shell corporation as defined in Rule 12b-2 under the Exchange Act. | aepp_8k.htm |
| 2017-07-25 | 8-K | 2017-07-25 | 1.01 Entry into a Material Definitive Agreement; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 On July 25, 2017, Advanced Environmental Petroleum Producers, Inc. (the “Company” or “AEPP”) and Oncolix, Inc. (“Oncolix”) amended the Agreement and Plan of Merger (the “Merger”) for the acquisition by AEPP of all the outstanding securities of Oncolix, a private clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian cancer. 5.03 See Item 1.01 of this Current Report on Form 8-K for proposed changes to the Articles of Incorporation of the Company. | aepp_8k.htm |
| 2017-07-24 | 8-K | 2017-07-18 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure | 1.01 On July 18, 2017, Advanced Environmental Petroleum Producers, Inc. (the “Company” or “AEPP”) entered into an Agreement and Plan of Merger (the “Merger”) for the acquisition of all of the outstanding securities of Oncolix, Inc., a private clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian cancer (“Oncolix”). 3.03 Immediately prior to the closing of the Merger, assuming the conditions to closing are met, AEPP will file Articles of Amendment to its Articles of Incorporation (the “Articles”) to create a designation of Series A Preferred Stock (substantially identical to the existing designation of Oncolix preferred stock). 5.03 See Item 3.03 of this Current Report on Form 8-K for proposed changes to the Articles of Incorporation of the Company. 7.01 On July 24, 2017, Advanced Environmental Petroleum Producers, Inc. (the “Company”) issued a press release announcing the approval of the Board of Directors of AEPP and the majority in interest of the stockholders of Oncolix of the Merger in which the Company will acquire all of the outstanding capital stock of Oncolix and assume of options and warrants to acquire Oncolix capital stock and debt convertible into capital stock. | aepp_8k.htm |
| 2017-06-28 | 8-K | 2017-06-28 | 7.01 Regulation FD Disclosure | 7.01 On June 28, 2017, Advanced Environmental Petroleum Producers, Inc. (the “Company”) issued a press release announcing an update of its corporate activities. | aepp_8k.htm |
| 2017-04-11 | 8-K | 2017-04-06 | 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.01 As previously reported in a Current Report on Form 8-K of Advanced Environmental Petroleum Producers, Inc. (the “Company,” “us,” “we,” “our” or words of similar meaning), filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2017 (the “Signing 8-K”), pursuant to a Stock Purchase Agreement dated as of March 6, 2017 (the “Purchase Agreement”) by and among Oncolix, Inc., a Delaware corporation (the “Purchaser”), Brian K. Kistler, at that time our majority shareholder and sole executive officer, employee and director on our Board of Directors (the “Board”), New Opportunity Business Solutions, Inc. a corporation whose sole shareholder is Mr. Kistler (“NOBS,” and together with Mr. Kistler, collectively, the “Seller”) and the Company, the Seller agreed to sell 61,465,130 shares of our common stock owned by the Seller (approximately 66% of our issued and outstanding shares) to the Purchaser for a purchase price of $315,000 (the “Share Acquisition”). 5.02 On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company. | aepp_8k.htm |
| 2017-04-04 | 8-K/A | 2017-03-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 Pursuant to a Stock Purchase Agreement dated as of March 6, 2017 by and among Oncolix, Inc., a Delaware corporation (the “Purchaser” or “Oncolix””), Brian K. Kistler our majority shareholder and sole executive officer, employee and director on our Board, New Opportunity Business Solutions, Inc. a corporation whose sole employee, officer, director, control person and shareholder is Mr. Kistler (“NOBS,” and together with Mr. Kistler, collectively, the “Seller”) and the Company (the “SPA”), the Seller will sell 61,465,130 shares of our common stock owned by the Seller (approximately 66% of our issued and outstanding shares) to the Purchaser for a purchase price of $315,000 (the “Share Acquisition”). | form8k_amendment04042017.htm |
| 2017-03-22 | 8-K | 2017-03-22 | 8.01 Other Events | 8.01 This Current Report on Form 8-K amends, to the extent provided herein, the Current Report on Form 8-K of Advanced Environmental Petroleum Producers, Inc. (the “Company,” “we”, “us” or “our”) filed with the Securities and Exchange Commission (the “SEC”) on or about March 14, 2017. | aeppform8k_032102017.htm |
| 2017-03-14 | 8-K | 2017-03-14 | 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | aepp_form8krecontrolchange.htm | |
| 2017-02-14 | 8-K | 2017-02-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | form8k_juytermination.htm | |
| 2017-02-14 | 8-K | 2017-02-13 | 1.02 Termination of a Material Definitive Agreement | 1.02 Effective immediately, the October 24, 2015 announcement that the Company had entered into an agreement to acquire 100% of the issued and outstanding shares of 1923285 Alberta, Ltd. (an Alberta corporation) is hereby cancelled. | form8k_reperutermination.htm |
| 2017-01-13 | 8-K | 2017-01-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 8.01 On January 9, 2017, the Company changed its principal address to 215 North Jefferson Box 591, Ossian, Indiana 46777. | aepp8kceochange.htm |
| 2016-08-19 | 8-K | 2016-08-16 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 There were no disagreements between the Company and S&C for the two most recent fiscal years and the March 31, 2016 interim filing on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of S&C, would have caused to make reference to the subject matter of the disagreement in connection with its report. | aepp_8k.htm |
| 2016-07-20 | 8-K | 2016-07-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | aepp_8kdebtsettement.htm |
| 2016-07-08 | 8-K | 2016-07-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | aepp_8kperutea.htm |
| 2016-05-20 | 8-K | 2016-05-18 | 8.01 Other Events | 8.01 Pursuant to the agreement to acquire 100% of the issued and outstanding shares of 1923285 Alberta Ltd. for 65,600,000 shares of the common stock announced on October 24, 2015 (the "Agreement"), the Company confirms that the Company has received and accepted an extension request to complete the required due diligence until June 30, 2016. | aepp_8kleaseupdate.htm |
| 2016-04-29 | 8-K/A | 2016-02-12 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On October 24, 2015, the Company announced that it had entered into an agreement to acquire 100% of the issued and outstanding shares of 1923285 Alberta Ltd. ("Alberta") for 65,600,000 shares of the Company’s common stock. 5.02 On February 11, 2016, the Board of Directors of Advanced Environmental Petroleum Products, Inc., a Florida corporation (the "Company"), accepted the consent from and approved the appointment of Loong Yip Juy as the President of the Company. | aepp_8ka042916.htm |
| 2016-02-16 | 8-K | 2016-02-16 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On October 24, 2015, the Company announced that it had entered into an agreement to acquire 100% of the issued and outstanding shares of 1923285 Alberta Ltd. ("Alberta") for 65,600,000 shares of the Company’s common stock. 5.02 On February 11, 2016, the Board of Directors of Advanced Environmental Petroleum Products, Inc., a Florida corporation (the "Company"), accepted the consent from and approved the appointment of Loong Yip Juy as the President of the Company. | aepp8kjuyappt.htm |
| 2015-10-30 | 8-K | 2015-10-30 | 4.01 Changes in Registrant's Certifying Accountant | form8kreaccountant.htm | |
| 2015-10-29 | 8-K | 2015-10-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | aeppform8kperuleasedeal.htm |
| 2015-10-16 | 8-K | 2015-10-13 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On September 29, 2015, the Company filed the Issuer Company-Related Action Notification Form with FINRA to change its name from Electric Vehicle Research Corporation to Advanced Environmental Petroleum Producers Inc. and to request a voluntary change of its symbol. 5.07 On September 10, 2015, the majority shareholders of the Company approved a reverse stock split of one for 1,000 (1:1000) of the Company's total issued and outstanding shares of common stock (the “Stock Split”) and a change in the name of the Company from "Electric Vehicle Research Corporation." to "Advanced Environmental Petroleum Producers Inc. " (the "Name Change"). | evrc_8knamechange.htm |
| 2014-12-17 | 8-K | 2014-11-24 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 24, 2014 Electric Vehicle Research Corporation ("EVRC") entered into an Engagement Letter (the "Engagement Letter") with Sigur Capital ("Sigur") where Sigur has been engaged to act as the lead advisor to Electric Vehicle Research Corp. working in close consultation with the Company and some of its existing advisers. | evrc8k_sigurengagement.htm |